Latest Cost Control News

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

Greatland Resources delivered a record $260 million cash build in the March 2026 quarter, underpinned by 82,723 ounces of gold production at a $2,056/oz AISC and a 150% increase in Telfer's Mineral Resource Estimate to 8 million ounces gold.

Fortescue Ltd has greenlit a US$680 million expansion of its Pilbara renewable energy infrastructure, aiming to deliver 200MW of additional capacity by 2028 to meet rising industrial and data centre demand while advancing its Real Zero by 2030 emissions target.

Qoria Limited has increased its equity placement to US$100 million, backed by insiders, to support aggressive AI investment and integration with Aura. The combined group reports robust ARR growth and reiterates FY26 guidance amid ongoing merger preparations.

Yancoal Australia posted a record 38.6 million tonnes of attributable saleable coal in 2025, up 5% on 2024, but net profit after tax plunged 64% to A$440 million amid softer coal prices. The miner maintained disciplined cost control and declared A$769 million in fully franked dividends.

DigitalX Limited closed the March 2026 quarter with A$59.5 million in liquid assets, unveiling a A$30 million strategic investment program and delivering record revenue from its Sell My Shares platform, signalling a pivot towards disciplined capital deployment and sustainable growth.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Pureprofile delivered a robust Q3 FY26 with 17% revenue growth and a 67% spike in EBITDA, driven by strong international demand and a doubling of platform revenue. The company reaffirmed its FY26 guidance amid ongoing macroeconomic caution.

Bubalus Resources reports encouraging gold intercepts from maiden Avon Plains drilling while streamlining its portfolio to prioritise Victorian assets and critical minerals projects. The company maintains a solid $3 million cash buffer amid cost cuts and plans multiple exploration campaigns in the coming quarters.

Genesis Energy's Q3 FY26 results highlight a sharp rise in hydro generation and electricity netback, offset by lower electricity sales and customer numbers amid strategic portfolio shifts. The company advances renewables and digital projects while cutting thermal output and oil production, prompting a boost in EBITDAF guidance.